by The human microbiome refers to the collection of microorganisms such as bacteria, viruses, fungi, and their genetic elements that reside in healthy human habitats such as the gastrointestinal tract, skin, and genitourinary areas. Key companies are engaged in developing microbiome-based drugs, therapeutics and diagnostics to fight various diseases. For instance, Seres Therapeutics is developing microbiome therapies that utilize a consortium of live commensal microbes targeting immune mechanisms in Clostridium difficile infection and inflammatory bowel disease.
The global human microbiome market is estimated to be valued at US$ 730 million in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The global human microbiome market is expected to be flourished by rising investments in microbiome research. For instance, in 2021 the total funding raised by microbiome companies reached US$ 2.8 billion, more than double from 2020 levels. This rise in funding is expected to fuel research around developing disease modifying microbiome therapies and support ongoing clinical trials. Another key driver for the market growth is increasing adoption of microbiome profiling techniques in precision medicine. Microbiome profiling tools provide insights on the relationship between the microbiome and various health conditions, thereby helping develop targeted therapies. With growing focus on nutrition and diet, probiotic supplements market is also witnessing significant expansion, thus contributing towards the market growth over the forecast period.
Segment Analysis
The global human microbiome market is dominated by the probiotic supplement sub-segment, which holds over 30% share of the market. Probiotic supplements are widely consumed as they help maintain a balanced gut microbiome and improve overall digestive health. The growing awareness about the importance of gut health and immunity is driving the growth of this sub-segment.
PEST Analysis
Political: The regulations around research involving the human microbiome differ in various regions. Favourable regulations support the growth of the market.
Economic: The rising healthcare spending and growing personal incomes have increased the affordability of probiotic supplements and testing kits in recent years, positively impacting the market.
Social: Changing lifestyle habits and increasing prevalence of lifestyle diseases have highlighted the importance of gut and overall health. This has increased the focus on microbiome-based diets and supplements.
Technological: Advancements in sequencing technologies and bioinformatics have enabled comprehensive analysis of the microbiome. This is supporting development of more targeted microbiome-based therapies and diagnostics.
Key Takeaways
The Global Human Microbiome Market Size is expected to witness high growth in the forecast period driven by factors such as increasing research funding, growing microbiome-based therapeutic pipeline and rising awareness.
From a regional perspective, North America dominates the market currently owing to presence of major players and availability of advanced diagnostic technologies. Europe is also a significant market supported by growing geriatric population and rising burden of chronic diseases.
Key players operating in the human microbiome market include Enterome Bioscience, Seres Therapeutics, Vedanta Biosciences, Osel, Merck and Forest Laboratories, Synlogic, Vedanta Biosciences, Synthetic Biologics/GlycoBioSciences, BiomX, 4D Pharma. These players are heavily investing in R&D to develop microbiome-based therapies and expand their footprints in this emerging market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
